Development

SynOx's CSF-1R antibody emactuzumab set for approval filing in TCGT after strong Phase III

SynOx Therapeutics reported that emactuzumab met both primary and secondary endpoints in the Phase III TANGENT study in tenosynovial giant cell tumor, with...

Edited by Robert McTiernan··3 min read

SynOx Therapeutics reported that CSF-1R-targeted antibody emactuzumab met both primary and secondary endpoints in the Phase III TANGENT study in tenosynovial giant cell tumor (TCGT), with statistically significant improvements in tumor response and patient-reported functional outcomes versus placebo. SynOx indicated that the data will support a Biologics License Application submission to the FDA in the second half of 2026.

The TANGENT trial (NCT05417789) is a global, randomized, double-blind, placebo-controlled Phase III study enrolling adults with biopsy-confirmed localized or diffuse TGCT for whom surgery would worsen functional outcomes or carry high recurrence risk.

Emactuzumab, dosed at 1,000 mg intravenously every two weeks for five doses over eight weeks, produced statistically significant improvements in objective response rate by RECIST v1.1 — the primary endpoint — at six months. Key secondary endpoints, including Tumor Volume Score, PROMIS-PF physical function T-score, range of motion, pain, and stiffness, also met significance thresholds. The company did not disclose specific response rate figures in the topline release, with full data expected at an upcoming medical meeting. The safety profile was consistent with prior clinical experience, with no new signals identified.

The target rationale

The mechanistic rationale for emactuzumab in TGCT is well-established. TGCT is driven by pathological overexpression of CSF1, the primary ligand for CSF-1R, which recruits and sustains the macrophage-rich tumor microenvironment that defines the disease. Emactuzumab is a high-affinity anti-CSF-1R monoclonal antibody that blocks receptor activation and depletes tumor-promoting macrophages — the same pathway targeted by the two approved oral agents in this space, pexidartinib (Turalio) and vimseltinib (Romvimza).

Pexidartinib, a multi-kinase small-molecule inhibitor, received FDA approval in 2019 on the basis of the ENLIVEN trial, which showed a 38% objective response rate versus 0% with placebo. Its label carries a boxed warning for serious and potentially fatal hepatotoxicity and requires a REMS program. Vimseltinib, a more selective switch-control CSF-1R kinase inhibitor with twice-weekly oral dosing, gained approval in February 2025 following positive Phase III MOTION data, posting a 46% response rate versus 4% with placebo, without the hepatotoxicity profile that constrained pexidartinib's uptake.

The AllSci BriefSystematic R&D and deal news. Daily.

Both approved agents require continuous, indefinite administration. That is the structural feature emactuzumab is designed to disrupt. SynOx is positioning the antibody as a short-course induction therapy — eight weeks of treatment intended to produce durable disease control without ongoing dosing. The TANGENT data, as described in the topline release, show that functional benefits were observed rapidly and persisted beyond the treatment window, though the durability follow-up period extends to 18 months and full characterization is ongoing.

The clinical logic for a finite-course approach is grounded in the disease context. TGCT is non-malignant but locally aggressive, primarily affecting patients between ages 35 and 50 — a population expected to live with the disease, and its treatment, for decades. Chronic oral TKI therapy in this setting carries cumulative tolerability risk and daily adherence burden that are not trivial considerations when the underlying condition is not life-threatening. The TANGENT protocol also allows retreatment with open-label emactuzumab for patients who progress during the follow-up phase, preserving a rescue option without committing patients to indefinite systemic therapy from the outset.

The TANGENT response rate — once disclosed in full — cannot be directly benchmarked against the ENLIVEN or MOTION figures. What can be assessed structurally is the modality distinction: emactuzumab's antibody format offers receptor-level blockade rather than intracellular kinase inhibition, a mechanistic difference that may carry different resistance and tolerability implications, though no comparative data exist.

The TGCT market is small by oncology standards — an estimated 200,000 patients in the US and 179,000 in the EU plus UK, with an incidence of approximately 50 per million — but the disease's chronicity and the working-age demographic create a commercially relevant patient population with long treatment horizons. SynOx is privately held and backed by Forbion, Gilde Healthcare, HealthCap, Bioqube Ventures, and Medicxi.

Spot something wrong? Report an issue with this article